IL279810B2 - Heteroaryl-modified sulfonamide compounds and their use as medicinal agents - Google Patents
Heteroaryl-modified sulfonamide compounds and their use as medicinal agentsInfo
- Publication number
- IL279810B2 IL279810B2 IL279810A IL27981020A IL279810B2 IL 279810 B2 IL279810 B2 IL 279810B2 IL 279810 A IL279810 A IL 279810A IL 27981020 A IL27981020 A IL 27981020A IL 279810 B2 IL279810 B2 IL 279810B2
- Authority
- IL
- Israel
- Prior art keywords
- methyl
- amino
- sulfonamide
- compound
- thiazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/76—Nitrogen atoms to which a second hetero atom is attached
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862725956P | 2018-08-31 | 2018-08-31 | |
| PCT/US2019/048917 WO2020047323A1 (en) | 2018-08-31 | 2019-08-29 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| IL279810A IL279810A (en) | 2021-03-01 |
| IL279810B1 IL279810B1 (en) | 2024-11-01 |
| IL279810B2 true IL279810B2 (en) | 2025-03-01 |
Family
ID=67953876
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL279810A IL279810B2 (en) | 2018-08-31 | 2019-08-29 | Heteroaryl-modified sulfonamide compounds and their use as medicinal agents |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US10981905B2 (enExample) |
| EP (1) | EP3844150A1 (enExample) |
| JP (1) | JP7450606B2 (enExample) |
| KR (1) | KR20210054510A (enExample) |
| CN (1) | CN112638879B (enExample) |
| AU (1) | AU2019331005B2 (enExample) |
| BR (1) | BR112021000209A2 (enExample) |
| CA (1) | CA3110853A1 (enExample) |
| CL (1) | CL2021000443A1 (enExample) |
| CO (1) | CO2021001433A2 (enExample) |
| CR (1) | CR20210099A (enExample) |
| DO (1) | DOP2021000031A (enExample) |
| EA (1) | EA202190395A1 (enExample) |
| EC (1) | ECSP21013035A (enExample) |
| IL (1) | IL279810B2 (enExample) |
| JO (1) | JOP20200337A1 (enExample) |
| MA (1) | MA53489A (enExample) |
| MX (1) | MX2021001380A (enExample) |
| MY (1) | MY207670A (enExample) |
| NI (1) | NI202100013A (enExample) |
| PE (1) | PE20211066A1 (enExample) |
| PH (1) | PH12021550381A1 (enExample) |
| SG (1) | SG11202100109TA (enExample) |
| TW (1) | TW202115018A (enExample) |
| WO (1) | WO2020047323A1 (enExample) |
| ZA (1) | ZA202100593B (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3551626B1 (en) | 2016-12-09 | 2023-10-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| SG11202006296YA (en) | 2018-01-19 | 2020-08-28 | Cytokinetics Inc | Dihydrobenzofuran and inden analogs as cardiac sarcomere inhibitors |
| AU2019285184B2 (en) | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| JP7438148B2 (ja) | 2018-06-26 | 2024-02-26 | サイトキネティックス， インコーポレイテッド | 心臓サルコメア阻害剤 |
| EP3814343B1 (en) | 2018-06-26 | 2023-01-11 | Cytokinetics, Inc. | Cardiac sarcomere inhibitors |
| US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| KR20240015622A (ko) | 2021-03-04 | 2024-02-05 | 싸이토키네틱스, 인코포레이티드 | 심장 근절 억제제 |
| WO2024049179A1 (ko) * | 2022-08-31 | 2024-03-07 | 주식회사 아이엔테라퓨틱스 | 인비보 세포외 신경다발절 기록법을 이용한 전기생리학적 약효평가법 |
| AR133184A1 (es) * | 2023-07-07 | 2025-09-03 | Novartis Ag | Bloqueadores de canales de sodio |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180162868A1 (en) * | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5877193A (en) | 1996-07-19 | 1999-03-02 | Hoffmann-La Roche Inc. | Use of N-(4-aryl-thiazol-2-yl)-sulfonamides |
| AU741482B2 (en) | 1997-05-07 | 2001-11-29 | Allergan Pharmaceuticals International Limited | Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors |
| CA2349832A1 (en) | 1999-01-13 | 2000-07-20 | Warner-Lambert Company | Benzenesulfonamide derivatives and their use as mek inhibitors |
| ATE250932T1 (de) | 1999-07-16 | 2003-10-15 | Warner Lambert Co | Verfahren zur behandlung von chronischem schmerz durch verabreichung von einem mek hemmer |
| GB9928568D0 (en) | 1999-12-03 | 2000-02-02 | Zeneca Ltd | Chemical compounds |
| FR2836917B1 (fr) | 2002-03-11 | 2006-02-24 | Lipha | Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant en tant que medicaments utilisables dans le traitement des pathologies caracterisees par une situation de stress oxydatif |
| CA2744893A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as glucokinase activators |
| WO2004092123A2 (en) | 2003-04-10 | 2004-10-28 | Microbia, Inc. | Inhibitors of fungal invasion |
| WO2005000309A2 (en) | 2003-06-27 | 2005-01-06 | Ionix Pharmaceuticals Limited | Chemical compounds |
| CA2531418A1 (en) | 2003-07-08 | 2005-01-20 | Novartis Ag | Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds |
| KR20060073930A (ko) | 2003-08-08 | 2006-06-29 | 버텍스 파마슈티칼스 인코포레이티드 | 통증 치료시 나트륨 또는 칼슘 채널 차단제로서 유용한헤테로아릴아미노설포닐페닐 유도체 |
| HU227684B1 (en) | 2003-08-29 | 2011-11-28 | Sanofi Aventis | Adamantane and azabicyclo-octane and nonane derivatives and their use as dpp-iv inhibitors |
| WO2006066109A2 (en) | 2004-12-17 | 2006-06-22 | Takeda San Diego, Inc. | Hydroxysteroid dehydrogenase inhibitors |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| WO2007039171A1 (en) | 2005-10-06 | 2007-04-12 | Sanofi-Aventis | 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals |
| WO2007075895A2 (en) | 2005-12-21 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| KR101117931B1 (ko) | 2006-08-15 | 2012-04-12 | 에프. 호프만-라 로슈 아게 | 페닐, 피리딘 및 퀴놀린 유도체 |
| RU2474582C2 (ru) | 2006-10-19 | 2013-02-10 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Гетероарильные соединения, их композиции и их применение в качестве ингибиторов протеинкиназы |
| US8853250B2 (en) | 2007-07-13 | 2014-10-07 | Icagen, Inc. | Sodium channel inhibitors |
| JP5460589B2 (ja) | 2007-07-13 | 2014-04-02 | アイカジェン， インコーポレイテッド | ナトリウムチャネル阻害物質 |
| WO2009013171A2 (en) | 2007-07-24 | 2009-01-29 | F. Hoffmann-La Roche Ag | Heterocyclic antiviral compounds |
| US7935779B2 (en) | 2008-03-07 | 2011-05-03 | Great Eastern Resins Industrial Co., Ltd. | Synthesis of polyimides (PI) from poly-carbodiimides and dianhydrides by sequential self-repetitive reaction (SSRR) |
| NZ588983A (en) | 2008-06-25 | 2011-11-25 | Daiichi Sankyo Co Ltd | Carboxylic acid compound |
| EP2307412A2 (en) | 2008-07-01 | 2011-04-13 | Vertex Pharmaceuticals Incorporated | Heterocyclic derivatives as modulators of ion channels |
| GB0815947D0 (en) | 2008-09-02 | 2008-10-08 | Univ Dundee | Compounds |
| US20110294853A1 (en) | 2008-09-12 | 2011-12-01 | Benjamin Pelcman | Bis Aromatic Compounds for Use in the Treatment of Inflammation |
| CA2747419C (en) | 2009-01-12 | 2014-07-08 | Icagen, Inc. | Sulfonamide derivatives |
| WO2012004743A1 (en) | 2010-07-09 | 2012-01-12 | Pfizer Limited | Benzenesulfonamides useful as sodium channel inhibitors |
| BR112013003864B1 (pt) | 2010-08-20 | 2021-08-31 | Hutchison Medipharma Limited | Compostos de pirrolpirimidina, composição e uso dos mesmos |
| AU2012296529A1 (en) | 2011-08-17 | 2014-02-20 | Amgen Inc. | Heteroaryl sodium channel inhibitors |
| AU2012328561A1 (en) | 2011-10-28 | 2014-04-17 | Merck Sharp & Dohme Corp. | Benzoxazolinone compounds with selective activity in voltage-gated sodium channels |
| ES2586213T3 (es) | 2011-10-31 | 2016-10-13 | Xenon Pharmaceuticals Inc. | Compuestos de bencenosulfonamida y su uso como agentes terapéuticos |
| MX2014005304A (es) | 2011-10-31 | 2015-03-20 | Xenon Pharmaceuticals Inc | Biaril eter sulfonamidas y su uso como agentes terapeuticos. |
| US8889741B2 (en) | 2012-02-09 | 2014-11-18 | Daiichi Sankyo Company, Limited | Cycloalkane derivatives |
| WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
| US9376429B2 (en) | 2012-10-15 | 2016-06-28 | Daewoong Pharmaceutical Co., Ltd. | Sodium channel blockers, preparation method thereof and use thereof |
| AU2013334664A1 (en) | 2012-10-26 | 2015-05-07 | Merck Sharp & Dohme Corp. | N-substituted indazole sulfonamide compounds with selective activity in voltage-gated sodium channels |
| JP2015535251A (ja) | 2012-10-26 | 2015-12-10 | メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． | 電位作動型ナトリウムチャネルにおいて選択的活性を有するベンゾオキサゾリノン化合物 |
| TW201443025A (zh) | 2013-04-19 | 2014-11-16 | Pfizer Ltd | 化學化合物 |
| TW201512171A (zh) | 2013-04-19 | 2015-04-01 | Pfizer Ltd | 化學化合物 |
| US9212182B2 (en) | 2013-06-12 | 2015-12-15 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
| GB201310542D0 (en) | 2013-06-13 | 2013-07-31 | Antabio Sas | Compounds |
| WO2015035278A1 (en) | 2013-09-09 | 2015-03-12 | Bristol-Myers Squibb Company | RORγ MODULATORS |
| CN105611923B (zh) | 2013-09-10 | 2019-08-23 | 卓莫赛尔公司 | 用于治疗疼痛和糖尿病的钠通道调节剂 |
| WO2015077905A1 (en) | 2013-11-29 | 2015-06-04 | Merck Sharp & Dohme Corp. | Bicycloamine-substituted-n-benzenesulfonamide compounds with selective activity in voltage-gated sodium channels |
| CA2934473C (en) | 2013-12-23 | 2019-08-20 | Purdue Pharma L.P. | Indazoles and use thereof |
| CN106795149B (zh) | 2015-05-05 | 2019-09-24 | 上海海雁医药科技有限公司 | 双环取代的苯磺酰胺衍生物、其制法与医药上的用途 |
| CN108699015A (zh) | 2015-12-18 | 2018-10-23 | 默沙东公司 | 对电压门控性钠通道具有选择性活性的羟基烷基胺-和羟基环烷基胺-取代的二胺-芳基磺胺化合物 |
| BR112018012408A2 (pt) | 2015-12-18 | 2018-12-04 | Merck Sharp & Dohme | ?composto, composição, e, método para tratar um distúrbio de dor ou distúrbio de tosse ou de coceira aguda ou de coceira crônica? |
| CU24516B1 (es) | 2016-05-03 | 2021-05-12 | Bayer Pharma AG | Derivados aromáticos de sulfonamida útiles como medicamentos contra enfermedades asociadas con dolor |
| WO2017201468A1 (en) | 2016-05-20 | 2017-11-23 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| US10968210B2 (en) | 2016-11-17 | 2021-04-06 | Merck Sharp & Dohme Corp. | Diamino-alkylamino-linked arylsulfonamide compounds with selective activity in voltage-gated sodium channels |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| AU2019285184B2 (en) | 2018-06-13 | 2023-11-16 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
| MA53491A (fr) | 2018-08-31 | 2021-09-15 | Cytokinetics Inc | Inhibiteurs de sarcomes cardiaques |
| MA53488A (fr) | 2018-08-31 | 2021-12-08 | Xenon Pharmaceuticals Inc | Composés de sulfonamide substitués par hétéroaryle et leur utilisation en tant qu'inhibiteurs de canaux sodiques |
| US10981905B2 (en) | 2018-08-31 | 2021-04-20 | Xenon Pharmaceuticals Inc. | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |
-
2019
- 2019-08-29 US US16/556,055 patent/US10981905B2/en active Active
- 2019-08-29 PE PE2021000164A patent/PE20211066A1/es unknown
- 2019-08-29 MY MYPI2021000075A patent/MY207670A/en unknown
- 2019-08-29 EA EA202190395A patent/EA202190395A1/ru unknown
- 2019-08-29 MA MA053489A patent/MA53489A/fr unknown
- 2019-08-29 KR KR1020217005599A patent/KR20210054510A/ko active Pending
- 2019-08-29 IL IL279810A patent/IL279810B2/en unknown
- 2019-08-29 JO JOP/2020/0337A patent/JOP20200337A1/ar unknown
- 2019-08-29 MX MX2021001380A patent/MX2021001380A/es unknown
- 2019-08-29 EP EP19768963.1A patent/EP3844150A1/en not_active Withdrawn
- 2019-08-29 CA CA3110853A patent/CA3110853A1/en active Pending
- 2019-08-29 BR BR112021000209-0A patent/BR112021000209A2/pt unknown
- 2019-08-29 SG SG11202100109TA patent/SG11202100109TA/en unknown
- 2019-08-29 CN CN201980055649.4A patent/CN112638879B/zh not_active Expired - Fee Related
- 2019-08-29 CR CR20210099A patent/CR20210099A/es unknown
- 2019-08-29 JP JP2021510434A patent/JP7450606B2/ja active Active
- 2019-08-29 AU AU2019331005A patent/AU2019331005B2/en not_active Ceased
- 2019-08-29 WO PCT/US2019/048917 patent/WO2020047323A1/en not_active Ceased
-
2020
- 2020-02-07 TW TW109103817A patent/TW202115018A/zh unknown
-
2021
- 2021-01-27 ZA ZA2021/00593A patent/ZA202100593B/en unknown
- 2021-02-09 CO CONC2021/0001433A patent/CO2021001433A2/es unknown
- 2021-02-19 DO DO2021000031A patent/DOP2021000031A/es unknown
- 2021-02-22 CL CL2021000443A patent/CL2021000443A1/es unknown
- 2021-02-23 PH PH12021550381A patent/PH12021550381A1/en unknown
- 2021-02-24 US US17/183,401 patent/US11639351B2/en active Active
- 2021-02-25 NI NI202100013A patent/NI202100013A/es unknown
- 2021-02-25 EC ECSENADI202113035A patent/ECSP21013035A/es unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180162868A1 (en) * | 2016-12-09 | 2018-06-14 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
Non-Patent Citations (1)
| Title |
|---|
| PAOLA CIAPETTI AND BRUNO GIETHLEN ED, CAMILLE GEORGES WERMUTH, CHAPTER 15 - MOLECULAR VARIATIONS BASED ON ISOSTERIC REPLACEMENTS, THE PRACTICE OF MEDICINAL CHEMISTRY, 1 January 2008 (2008-01-01) * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11639351B2 (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | |
| US11299490B2 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| US11174268B2 (en) | Benzenesulfonamide compouds and their use as therapeutic agents | |
| US11325902B2 (en) | Benzenesulfonamide compounds and their use as therapeutic agents | |
| US10752623B2 (en) | Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors | |
| HK40049688A (en) | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents |